No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Regeneron’s Odronextamab BLA Resubmission Accepted for FDA Review
On 26 February 2025, Regeneron announced that the US FDA has accepted for review the resubmission of the BLA for odronextamab for the treatment of relapsed/refractory follicular